Patient empowerment by group medical consultations in the follow-up of breast cancer survivors and surveillance of women with a BRCA mutation

Patient empowerment by group medical consultations in the follow-up of breast cancer survivors and surveillance of women with a BRCA mutation - GMC trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON34236

Enrollment

344

Registered

2011-01-27

Start date

2011-04-05

Completion date

Unknown

Last updated

2025-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

GMC versus regular individual consultation

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Participants: patients in follow-up after breast cancer Women >= 18 years of age with histologically proven breast cancer. Primary treatment (surgery, radiotherapy, chemotherapy) completed maximally 5 years ago. ;Participants: women with a BRCA mutation Women >= 25 years of age with a proven BRCA1 or BRCA2 mutation. Carrier of a BRCA1 or BRCA2 mutation, diagnosed maximally two years before inclusion.

Exclusion criteria

Exclusion criteria: Participants: patients in follow-up after breast cancer Currently involved in a diagnostic work-up because of a suspicion of breast cancer, either primary or metastatic. A history of prophylactic mastectomy. Current psychiatric disease precluding consultations in a group. Insufficient command of the Dutch language to be able to follow a group discussion and/or to fill out a Dutch questionnaire. ;Participants: women with a BRCA mutation Currently involved in a diagnostic work-up because of a suspicion of breast cancer, either primary or metastatic. A history of prophylactic mastectomy. Current psychiatric disease precluding consultations in a group. Insufficient command of the Dutch language to be able to follow a group discussion and/or to fill out a Dutch questionnaire.

Design outcomes

Primary

Measure	Time frame
n.a.	—

Secondary

Measure	Time frame
n.a.	—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)